Powering Pharma: The Future of Contract Manufacturing and Research Services
The global pharmaceutical contract manufacturing and research services market was valued at USD 263.37 billion in 2024 and is expected to expand at a compound annual growth rate (CAGR) of 6.9% from 2025 to 2030. The market is primarily driven by the cost and time efficiencies of outsourcing, allowing pharmaceutical companies to focus more on their core competencies such as R&D, drug discovery, and commercialization. Leading market participants are continuously investing in infrastructure, workforce development, and advanced technologies to strengthen their positions and capture a larger share of outsourcing revenue. Moreover, the growing presence of end-to-end service providers offering value-added, integrated, and risk-sharing business models is further contributing to market expansion. The escalating complexity of modern drug development also fuels the demand for contract services. The increasing prevalence of biologics, biosimilars, HPAPIs, and personali...